Will Sarepta Therapeutics (SRPT) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/20
Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020GlobeNewsWire • 07/29/20
Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 07/24/20
Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare DiseasesGlobeNewsWire • 07/15/20
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business OfficerGlobeNewsWire • 06/30/20
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45GlobeNewsWire • 06/26/20
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Bank of America Napa Healthcare Conference (Transcript)Seeking Alpha • 06/24/20
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare DiseasesGlobeNewsWire • 06/22/20
Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 06/16/20
Sarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety HurdleThe Motley Fool • 06/15/20
Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA NeurologyGlobeNewsWire • 06/15/20
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2EGlobeNewsWire • 06/08/20
Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-SarcoglycanopathyGlobeNewsWire • 06/05/20
Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?Zacks Investment Research • 06/05/20
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/29/20